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Thesis Summary

Worldwide for both men and women, colorectal cancer ranks third in prevalence
and is responsible for around 694,000 deaths reported in 2012. In the United States, it is
the second leading cause of cancer related fatalities. Though there are many known risk
factors, such as family history and behavioral choices, colorectal cancer can develop
seemingly and unsuspectingly over a period of 10 to 15 years. As people age, growths,
known as adenomatous polyps, may form in the linings of the walls of the intestines
without any outward symptoms. These are typically harmless, but due to a series of
mutations within these tissues accumulating one after another, the regulation of growth
becomes disrupted and can lead to the beginning stages of colorectal cancer. This disease
is associated with a higher mortality rate because at the final stage of metastasis, or
spreading of cancerous cells to other organs, there are very few effective curative options.
The key to improving these outcomes is to further understand the mechanisms behind
metastasis and identify possible biomarkers for earlier and more successful treatment of
these patients.
One method to studying cancer progression is to utilize established cancerous cell
lines and observe which genes and proteins are more prevalent, suggesting they may have
a more prominent role in the pathways involved. By previously developing a highly
metastatic cell line, CT26-FL3, from a known lower metastatic cell line, CT26, and
implanting these cells in mice, microarray analysis of the entire genome showed that
lipocalin 2 (Lcn2) was one of the most highly expressed genes in comparison to mice that
did not undergo the transplantation of CT26-FL3 cells. Protein detection by western blot
analysis demonstrated an increase in Lcn2 as metastasis progressed.
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Since Lcn2 is heavily involved in cell to cell and tissue communication, secretion
into the media was investigated with both the lower and higher metastatic cell lines. This
was examined by performing a western blot to discover the normalized intracellular
expression of Lcn2 within the cells. As separate samples of these same cell lines grew to
normalized confluency, the media was collected and levels of Lcn2 were quantified,
revealing increased levels of overexpressed Lcn2 for CT26-FL3 in comparison to CT26.
In a conjunctional experiment with graduate student Daniel Hughes, expression of
intracellular mRNA within CT26 and CT26-FL3 derivatives produced similar results.
Within the stably transfected cell lines, it appears that Lcn2 has a positive association
with metastatic conditions for colorectal cancer.
In vivo experiments began with creating a plasmid that could transfer Lcn2 into
balb/c mice by in vivo electroporation. PBS by itself and 10µg of both the empty and
Lcn2 inserted plasmid was injected in order to discover a potential treatment in the stable
and continuous transfer of Lcn2. Mice were pre-bled days prior to electroporation. Once
Lcn2 is taken in and released in the bloodstream, mice were bled on days 1, 4, and 6 with
the subsequent data analyzed by ELISA, which is able to reveal the levels of protein
expression in collected serum via antibodies against Lcn2. In vivo electroporation
appears to be a promising treatment for investigating the effect of overexpressing Lcn2
on colon cancer metastasis to the liver. However, further varying treatments of dosage
must be explored for maximum effectiveness.
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Abstract

Metastasis, frequently from the colon to the liver, is the major cause of death with
colorectal cancer, reducing the five-year survival to less than 6%. Metastasis occurs due
to productive collaborations between tumor cells and host-derived cells in the tumor
microenvironment, where a pre-metastatic niche is created to prime for cancer cell
invasion into the target organ. In a highly metastatic colorectal cancer cell line implanted
into the cecum of Balb/c mice, microarray analysis showed lipocalin 2 (Lcn2) is one of
the most highly expressed proteins in the liver of tumor-bearing mice prior to metastasis.
When RT-PCR was performed, greater levels of Lcn2 mRNA were found in
highly metastatic cells in contrast to less metastatic cells that had been stably transfected.
Intracellular protein presence through western blot analysis and examination of media
secretion by ELISA illustrated increased levels of Lcn2 secretion with the same cell lines.
These results suggest that Lcn2 is highly associated with the promotion of colorectal
cancer metastasis to the liver, most likely secreted from liver cells, with increased levels
connected to the advancement of metastatic progression in vitro through the use of a
highly metastatic mouse model.
After the construction, verification, and large-scale endotoxin-free purification of
pSecTagA-Lcn2, this plasmid was utilized in in vivo electroporation of control groups
PBS only, 10 µg of pSecTagA vector only, and 10 µg of experimental group pSecTagALcn2 in order to explore the effectiveness of this method for the stable transfer and
constant expression of Lcn2 within the blood stream. After 6 days, the experimental
group expresses the greatest concentration of Lcn2 in comparison to both controls. In
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vivo electroporation seems to be a viable method of continuously overexpressing Lcn2 in
order to further examine colon cancer metastasis to the liver, though further studies must
take place to identify the ideal dosage for maximized overexpression.
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Introduction
Colorectal Cancer in Humans
Colorectal cancer is the third most common cancer in both men and women and
has accounted for approximately 694,000 deaths worldwide in 2012 (WHO 2014). It is
the second leading cause of cancer-related fatalities (CDC 2010) and the National Cancer
Institute estimates 136,830 new cases will be diagnosed in 2014 within the United States.
Coinciding with normal development over time, usually harmless tissue growths called
adenomatous polyps may develop in the linings of the intestinal walls. However, some of
these can become abnormally large and eventually become cancerous, though fewer than
10% progress to this stage (ACS 2011). This advancement is due to accumulated
mutations in genes that control growth and repair of cells in the mucosa, or innermost
layer, of the colorectal walls (NCI 2014).
Subsequently, these cancerous cells can affect nearby muscle layers and tissues,
circulating through lymph nodes and the blood, and finally invading other organs, such as
the liver or lungs (NCI 2011). This final step is known as metastasis. When observed
early on, these malignant tumors can be removed to prevent any life-threatening damage,
though the patient may experience recurrence later on. When patients are treated for
colorectal cancer prior to metastasis, the survival rate is high at about 74%. After
metastasis has occurred, the observed five year survival rate drops to six percent (ACS
2010). Unfortunately, those affected do not typically express outward symptoms of
metastasis and it is often diagnosed when very little can be done for the patient. Most
cases are treated with invasive surgery, including some chemotherapy, drug targeted
therapy, radiation therapy, and other non-surgical methods (ACS 2013).
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More research must be done on the biological and molecular hallmarks that direct
the early stages of metastasis, a stage that if diagnosed can provide the best opportunity
for therapy to block its progression. Metastasis takes place through multiple steps
mediated by complex interactions between the primary tumor and the target organ to
promote malignant growth (Sethi and Kang 2011). Recent studies have shown that prior
to the arrival of metastatic cancer cells to the target organ, molecular signals from the
primary tumor to the bone marrow compartment can direct the recruitment of bone
marrow derived cells to the target organ to establish a pre-metastatic niche, creating a
fertile environment for cancer cell invasion (Kaplan et al. 2005). It is therefore important
to identify the genetic and molecular changes taking place in the target organ in response
to the growth of cancer cells in the primary tumor. Understanding the mechanisms they
direct will ultimately aid in significantly lessening the impact of colorectal cancer on the
patient.

Previous Work
Previous studies in Dr. Peña’s laboratory have shown that the gene encoding
lipocalin 2, Lcn2, is one of the most highly expressed genes in the liver of tumor-bearing
mice prior to metastasis.
Use of a Highly Metastatic Mouse Model
Mouse models have greatly aided in the advancement of understanding biological
processes. Such models provide the proper environment to recognize the steps involved
in the various pathways of both normal functioning and especially disease. The
establishment of a highly metastatic colorectal cancer cell line, CT26-FL3, was
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developed by utilizing a mouse model of colorectal cancer metastasis to the liver. In vivo
education of flank cells was carried out by injecting a known low metastatic stable cell
line, CT26, into the flank cells of Balb/c mice. After two weeks, cells were cultured and
then implanted into the cecum of the same mice. Four to five weeks later, metastatic liver
cells were retrieved from the mice to be cultured and re-injected into the cecum. This
process was repeated using the metastatic liver cells for three rounds to achieve newly
educated CT26-FL3 cells. It is significant to use a highly metastatic cell line for research
to explore the conditions in which colorectal cancer metastasis to the liver occurs.

Figure 1: Process by which CT26 cells with low metastatic capabilities are educated to
become highly metastatic CT26-FL3 cells.
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Figure 2: Frequency of liver metastasis in mice bearing tumors from two isogenic cell
lines. Mice bearing tumors from the less metastatic CT26 parental cells had 10-fold less
frequency of liver metastasis compared to mice with tumors from CT26-FL3 cells.

Elevated Presence of Lipocalin 2
Gene expression analysis can determine which genes are expressed at
transcriptional levels under specific circumstances. One technique that employs this type
of profiling is microarray analysis, which allows for examination of the entire genome of
an organism in specific circumstances (Nature 2014). The highly metastatic colorectal
cancer cell line, CT26-FL3, was implanted into the cecum of Balb/c mice. Liver samples
from tumor bearing mice were analyzed prior to metastasis by microarray analyses to
identify genetic changes in the liver in response to tumor growth in the cecum. As a
control, liver samples from mice that have undergone sham surgery (no tumor cells
injected) were also analyzed. These studies were done using the Agilent mouse whole
genome microarray kit which allowed analysis of 44,000 genes. The results showed that
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Lcn2 is expressed 34-fold higher in the liver of tumor bearing mice as compared to the
liver in mice that have undergone sham surgery.
Rapid detection of the target gene at the translational level, or of the protein Lcn2,
was investigated by western blot analysis. Using balb/c mice that underwent the same
advancement to liver metastasis via CT26-FL3 cells, the circulating Lcn2 levels in blood
sera increased with tumor progression, but not in mice that had undergone sham surgery.

Figure 3: Western blot analysis of sera from tumor bearing mice at various stages of
metastasis.

Overview of Lipocalin 2
Lipocalin 2 (LCN2 in humans, Lcn2 in mice), also known as Neutrophil
Gelatinase Associated Lipolcain (NGAL), is a protein expressed in human neutrophils
and epithelial cells that is involved with a variety of processes within innate immunity
and several kinds of pathologies in response to stress. The broader family of lipocalins
contains a key structural feature, a β-barrel comprised of eight anti-parallel strands, which
is highly conserved (Rodvold et al. 2012). With this structure, small, hydrophobic
molecules are able to bind to lipocalins, including retinoids, hormones, and fatty acids,
creating the potential for cellular and tissue interaction via the transport of these small
molecules and defining the biological functionality of lipocalins (Rodvold).
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For more than two decades since its initial discovery and classification, the
protein LCN2 has become of increasing interest in biological research, including the
areas of antimicrobial immunity, inflammation, infectious disease, renal cardiac disease
or injury, and many other illnesses. Evidence has shown that LCN2 clearly plays a
pathophysiologic role in each of these diverse states (Li and Chan, 2011). Additionally, it
has also been abundantly present in a multitude of cancers, such as breast, pancreatic,
ovarian, prostate, and colorectal carcinomas, though the function of LCN2 remains
unclear in tumorigenesis (Rodvold).
There is conflicting evidence on their role in cancerous growth; some evidence
suggests that lipocalins can inhibit the proliferation of cancer cells (Lee et al. 2006),
while others suggest that they promote its progression (Leng et al. 2009). However, more
studies that have been conducted in recent years seem to suggest the latter, especially in
colorectal cancer. In 2009, Barresi et al. found that LCN2 can be characterized as a
negative prognostic marker related to a higher progression risk from stage I colorectal
cancer. Similarly, preoperative serum NGAL levels were elevated, especially with higher
neoplastic tissue volume, in patients with colorectal cancer than in comparison to a
normal population (Marti et al. 2013). In regards to more aggressive carcinomic stages,
LCN2 appears to be associated with higher rates of metastasis and poorer outcomes of
survival for colon cancer development and metastasis within affected patients (Maier et
al. 2014). Though these positive associations with advancement of colorectal cancer are
consistent, it is clear that further research must be undertaken to determine the role of
LCN2 in establishing cancerous conditions and promoting metastasis.
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Objectives of the Study
The overall goal of my project is to investigate the role of Lcn2 in promoting the
early stages of colon cancer metastasis to the liver. Using the mouse model described
above, I will assess Lcn2 protein levels in isogenic colon cancer cell lines with different
capabilities to metastasize. I will also begin to determine whether increasing levels of
Lcn2 coincides with the progression to early colorectal metastasis to the liver in vivo by
overexpressing Lcn2 levels in tumor cells and blood sera on tumor cell invasiveness and
ability to metastasize.
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Materials and Methods

Presence of Lcn2 in CT26 and CT26-FL3 Cell Lines by Western Blotting
Western blot analysis is a widely used technique that is able to detect the presence
of particular proteins depending on which antibodies are incorporated during the
procedure. To start, CT26, CT26-FL3, CT26 mCherry, CT26-FL3 mCherry, and stably
transfected cell lines of CT26 mCherry and CT26-FL3 mCherry with the pCMV6 empty
vector and pCMV6-Lcn2 in each were taken out of storage within the liquid nitrogen tank
and kept in a 37°C water bath for five minutes. 10 mL of DMEM with 10% fetal bovine
serum culture media was added to labeled petri dishes. 1 mL of thawed cells were then
added and distributed evenly. With a 20 mL pipette, media and cells were distributed
throughout the dish. All dishes were then placed in a 37°C incubator to grow. After two
days, cells were broken up by single cell suspension. They were first washed with 5mL of
HBSS and then the liquid was aspirated. 1mL was added and allowed to react with cells
for 30 seconds. Single cell suspension was observed under the microscope at 40X. 5 mL
of DMEM culture media was then added to stop the reaction and was mixed with culture
well. All culture was transferred to sterile 15 mL test tubes and centrifuged at 2000 rpm
for 4 minutes. The medium was aspirated and the pellet was agitated manually. 5 mL of
PBS was added in each test tube, vortexed, and then centrifuged at 2000 rpm for 4
minutes. These last two steps were repeated. Afterward, 1 mL of PBS was used to
separate the cells in the pellets of each test tube and mixed to then be transferred to 1mL
Eppendorf tubes. These were centrifuged at 2000 rpm for 4 minutes and the PBS

16
supernatant was aspirated as closely as possible. All samples were then stored at -80°C
for future usage.
In order to test the concentration of each cell in order to normalize in preparation
for western blotting, cells were broken with respective protein concentrations measured
in a spectrophotometer (Beckman DU-600).200 µL of Mammalian Protein Extraction
Reagent and 1 mL of 500X Protease Inhibitor were both added to each sample after they
were thawed. After being extensively mixed by pipetting and vortexing, they were placed
on ice for 10 minutes and then in the low temperature centrifuge at 11,000 rpm for 1 hour
at 4°C. 200 µL of Bio-Rad Protein Assay Dye Reagent Concentration, 797 µL of
deionized water, and 3 µL of each protein sample were analyzed and corresponding
concentration readings recorded in µg/mL.
To prepare these samples for western blot analysis, previous protein
concentrations are normalized in order to have even distribution of overall protein present
in loading samples. All are boiled at 99°C for 10 minutes. 10 µL of Bio Rad Plus
Precision Dual Standards ladder and 18 µL of samples were added to wells of pre-made
gels and immersed in 1X SDS Page Buffer. This gel ran at 200V for 30 minutes.
Afterward, the gel was removed and added to sandwich of filter paper and transfer
membrane, somewhat immersed in transfer buffer, into the Semi-Dry Transfer TransBlot. This ran at 15V for 1 hour. During this time, the first cocktail composed of 0.5g of
Bio-Rad Blotting-Grade Blocker Nonfat dry milk was combined with 9.5 mL PBST to
make 5% milk in PBST. After successful membrane transfer, 5% milk in PBST was
added to the membrane, shaking at room temperature for 30 minutes. A second cocktail
composed of 0.5g BSA, 9.5mL PBST and 20 µL of the first antibody, R&D Mouse
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Lipocalin-2/NGAL Affinity Purified Polyclonal Goat IgG Antibody (diluted 1:500) was
added to membrane after first washing with 10 to 20 mL PBST 3 times. The membrane
was left shaking at room temperature for 1 hour. The first antibody was then washed off
with 10 to 20 mL PBST four times, lasting 10 minutes each. A third cocktail with 0.5g
BSA, 9.5 mL PBST and 2 µL of the second antibody, Bio-Rad EIA Grade Affinity
Purified Rabbit Anti-Goat IgG (H+C)-HRP Conjugate (diluted 1:5000), was added to the
membrane shaking for 30 minutes at room temperature. The membrane was then washed
against with 10 to 20 mL PBST for twice for 5 minutes and 10 minutes. 500 µL of each
Immobilin Western Chemiluminescent HRP Substrate was added to the membrane and
exposed for 10 seconds. In order to test for β-actin levels, a protein conserved in all cells,
to ensure for even loading, the membrane was first washed with PBST twice for 5
minutes. A first cocktail of 0.2g BSA, 9.8 mL PBST, and 2 µL of the first antibody,
mouse (diluted 1:5000) was added for 30 minutes, shaking at room temperature. This was
followed by two PBST washes at 5 minutes each. A second cocktail of 0.2g BSA, 9.8 mL
PBST, and 2 µL of second antibody, anti-mouse (diluted 1:5000) was added for 20
minutes, shaking at room temperature, followed by two PBST washes at 5 minutes each.
1mL of each ECL Western Blot Detection reagent was mixed and added to the
membrane, later exposed for 30 seconds. Images were quantified with Image J provided
by the National Institutes of Health.

Analysis of Lcn2 Secretion into the Media by ELISA
Followed procedure for waking up cells with same cell lines as previously
mentioned, up until termination of single cell suspension, adding split cells to labeled 4,
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6-well plates. Counted with hemacytometer in order to plate around 200,000 cells per
well on each plate. On subsequent days, media was collected from samples when they
each reached around 70% to 80% confluency, as consistently as possible. Media was
collected with 5 mL syringe to inhibit passage of cells. Samples were stored in 15 mL
sterile test tubes at -80°C. The procedure from R&D Systems Quantikine ELISA Mouse
Lipocalin-2/NGAL kit was then followed. This procedure follows a sandwich ELISA
model where the sample is first recognized by a detecting antibody, with added first and
second antibodies on top, followed by the enzyme-substrate reaction with the enzyme
attached to the second enzyme and added substrate. All reagents and samples were
brought to room temperature. Standards were created as well as reagents Mouse
Lipocalin-2 Control reconstituted, Wash buffer made, and standards from Mouse
Lipocalin-2 Standard combined with Calibrator Diluent RD5-24 (1X). 50 µL of both
Assay Diluent RD1-34 and standards, controls, and samples were added to each well.
They were then covered and incubated for 2 hours at room temperature on the bench top.
Each well was then aspirated and washed with 400 µL Wash Buffer for a total of four
washes. Next, 100 µL of Mouse Lipocalin-2 Conjugate was added to each well with all
wells covered and incubated for another 2 hours at room temperature on the bench top.
The aspiration and washing step was repeated. 100 µL of Substrate Solution was added to
each well and incubated for 30 minutes at room temperature, protecting from light. A
color change was subsequently observed. 100 µL of Stop Solution was then added to
each well, tapping the plate for thorough mixing. The optical density was immediately
determined with a microplate reader at 450 nm, with wavelength correction at 540 nm
twice. All data analysis was done on Microsoft Excel and ReaderFit.
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Injection of DNA into Mice by In Vivo Electroporation
To increase the serum levels of LCN2 in balb/c mice, intramuscular in vivo
electroporation was performed using the LCN2 plasmid pSecTagA purified under
endotoxin free conditions.

Figure 4: Restriction map of pSecTagA-Lcn2 vector.

20
Purification of pSecTagA and pSecTagA-Lcn2 DNA was performed with
Promega Pure Yield Plasmid Miniprep System. This procedure allows for the cloning of
pSecTagA vector with Lcn2 DNA in E. coli cultures after pSecTagA has been ligated
with Lcn2. The bacteria are able to incorporate the vector and target DNA after quickly
heat shocking and placing back on ice. Clones are selectively grown by the addition of
antibiotic Hygromycin B, which the pSecTagA vector is resistant to. Well-formed
colonies are chosen for further growth with incubation at 37°C to create concentrated
inoculum. Subsequently, Qiagen Plasmid Plus Giga Kit was used for large scale
endotoxin-free purification of pSecTagA and pSecTagA-Lcn2 to prepare for this
experiment. The concentration of Lcn2 DNA was measured by a spectrophotometer.

Figure 5: Verification of Lcn2 DNA within pSecTagA vector transformants. This is a
picture taken from agarose gel after restriction enzyme digestion. On the left is the
“DNA” ladder that serves as a control to compare molecular weights of DNA fragments.
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Figure 6: Method of in vivo electroporation for varying dosage treatments.

Prior to surgery, the mice were anesthetized from inhalation of 5% isoflurane in
oxygen delivered at 1 L/minute. As the mice were each put into the induction chamber,
the concentration was lowered to 2.5% in oxygen. When successfully anesthetized, the
mice were placed on the sterile operating table with a nose cone delivering the same
concentration of isoflurane in oxygen. When laid down on its back, the thigh hair of the
mice is shaved and a small incision is made in the skin at the bottom of the thigh just
above the knee. This slit is expanded by further careful handling of scissors to uncover
fatty tissue which was must be cut to expose the quadriceps muscle. 10 µg of pSecTagA
or pSecTagA-Lcn2 were injected in a final volume of 15 or 30 µL PBS into the
quadriceps, while holding the syringe vertically and perpendicular to the muscle and
quickly pulling out afterwards. The BTX ECM 830 ElectroSquare Porator applied pulses
of electricity at 100V for 50 milliseconds to allow the muscle to take in the plasmid and
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consequently express Lcn2 protein to be secreted into the bloodstream. Animal
procedures have been approved by the USC Institutional Animal Care and Use
Committee.
To determine kinetics of Lcn2 expression after electroporation, 9 balb/c mice, all
born in January, were electroporated: 3 with PBS, 3 with pSecTagA vector at 10µg, and 3
with pSecTagA-Lcn2 at 10µg. Blood samples were taken from these mice days prior to
electroporation for a pre-bleed sample, and then on days 1, 3, and 6 following surgery.
Blood samples were obtained from the retro-orbital sinus using capillary tubes which
were then centrifuged for 5 minutes to separate red blood cells from blood sera
containing Lcn2. Sera samples were stored at -80°C until further analysis.

Analysis of Serum Lcn2 Levels by ELISA
Enzyme-linked immunosorbent assay (ELISA) is a relatively rapid method of
qualitative detection and quantitative measurement of protein levels. The blood sera was
first allowed to clot for 2 hours at room temperature. It was then spun at 2000 rpm for 20
minutes. The kit used was ABCAM Lipocalin-2 / NGAL Mouse Elisa Kit, which first
instructed to create reagents and proper conditions including 0.01M PBS as washing
buffer, dilution of all samples, reconstituting mouse Lcn2 standard of 10000 pg/mL to
create new standards from 156 pg/mL to 5000 pg/mL, biotinylated anti-mouse Lcn2
antibody and working solution both diluted, avidin-biotin-peroxidase complex (ABC) and
working solution diluted, noting that ABC and TMB color developing agent had to be
pre-warmed In 37°C for 30 minutes before usage. Standards, their duplicates, and
properly diluted sera samples were aliquoted 100 L per well. The plate was then sealed
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and incubated at 37°C for 90 mins. Afterward, the cover was removed, with the plate
content discarded and blotted onto paper towels. 100 L of biotinylated anti-mouse
LCN2 antibody working solution was then added into each well and incubated at 37°C
for 60 mins. The plate content was discarded and the plate was washed 3 times with
created washing buffer, each time allowed to stay in wells for 1 minute. Buffer was
discarded and plate blotted. 100

L of ABC working solution was added into each well

and incubated at 37°C for 30 mins. The plate content was discarded and the plate was
washed 5 times with washing buffer, each time allowing to stay in wells for 1 to 2 mins.
Buffer was discarded and plate blotted. 90

L of TMB color developing agent was added

into each well and incubated at 37°C for 20 to 25 mins. Next, 100

L of TMB stop

solution was added into each well. Observe color change to yellow immediately. OD
absorbance was read at 450 nm using BioTek’s Epoch Micro-Volume Spectrophotometer
System and concentration of standard solution in pg/mL was graphed against optical
density readings of standards. All data was analyzed on Microsoft Excel.
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Results

Intracellular Lcn2 in CT26 and CT26-FL3 Cell Lines by Western Blotting

Figure 7: CT26 and CT26-FL3 cells stably expressing high levels of Lcn2.

The presence of Lcn2 is confirmed in stably transfected CT26 and CT26-FL3
associated cell lines with the pCMV6 and pCMV6 Lcn2 vectors by western blot analysis.
Figure 4 illustrates CT26, CT26 mCherry, CT26 mCherry pCMV6 empty vector, CT 26
mCherry pCMV6 Lcn2, CT26-FL3, CT26-FL3 mCherry, CT26-FL3 mCherry pCMV6
empty vector, and CT 26-FL3 mCherry pCMV6 Lcn2 with their associated Lcn2 and
loading control β-actin occurrence. This data indicates relatively the same amount of
Lcn2 expressed intracellularly for each cell line.
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Figure 8: Lcn2 protein levels from western blot normalized against β-actin loading
control.

Using the program Image J provided by the National Institutes of Health, it is
possible to quantify the results from western blot analysis. Though there are variations
within the Lcn2 protein expression of each CT26 derived cell line, these results must be
placed against the expression of the loading control indicative of the amount of sample
added. Once the expression of the β-actin, a protein which is normally expressed and
highly conserved, is also determined and compared with the coinciding expression of
Lcn2 for each cell line, it is clear that these differences are caused by the volume of
sample added. Therefore, within each of these cell lines, the intracellular levels of Lcn2
expressed are about the same, though this is not indicative of a difference for the Lcn2
protein that may be transcribing and ultimately secreted extracellularly in order to
communicate with other cells or tissues.
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Levels of Lcn2 Secretion from CT26 and CT26-FL3 Cell Lines

Figure 9: Concentration of Lcn2 (pg/mL) secreted in harvested media by stably
transfected CT26 and CT26-FL3 cell lines.

Results from examining secretion of Lcn2 into the media of cultured cells reveal
several points of interest. As expected of the lower metastatic cells, with a success rate of
around 5%, the levels of Lcn2 secretion are almost nonexistent, whereas with the higher
metastatic cell line, with a success rate of around 90%, Lcn2 concentration are more
prevalent even without overexpression. Within both groups of cell lines, there is a clear
distinction in overexpression of CT26 and CT26-FL3 mCherry pCMV6-Lcn2 cells and
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their control counterparts, indicative of successful overexpression during the process of
transfection. What is most notable is the delineation between these two groups; the level
of overexpression for CT26-FL3 mCherry pCMV6-Lcn2 is significantly higher than that
of CT26 mCherry pCMV6-Lcn2, suggesting a positive correlation of Lcn2 protein
secretion for conditions prone to metastasis.

Lcn2 mRNA Expression from CT26 and CT26-FL3 Cell Lines

Figure 10: mRNA transcription levels of Lcn2 within CT26 derived cell lines.

In a conjunctional experiment with graduate student Daniel Hughes, real-time
polymerase chain reaction (RT-PCR) was used to measure intracellular levels of Lcn2
mRNA transcription. This study shows increased Lcn2 transcription for the
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overexpressing plasmids of each respective cell lines, as well as greater mRNA
expression between the lower metastatic CT26 and the higher metastatic CT26-FL3 cells.

Kinetics of Lcn2 Expression During Time Course Experiment

Figure 11: Concentrations of Lcn2 for each control and experimental group averaged
during in vivo electroporation experiment.

Results from ELISA analysis of in vivo electroporation of control and
experimental groups show differences in Lcn2 expression after collecting blood sera at
various time points. It should be noted that initial levels of Lcn2 expressed in blood sera
differ in general as Lcn2 is naturally expressed in blood neutrophils. The highest
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expression of Lcn2 actually occurs one day after experimentation with the PBS sham
control group. This is most likely due to a response in inflammation following surgery.
On average, the PBS group also has the lowest concentration of Lcn2 found 6 days after
in vivo electroporation. Differences between these groups can be further elucidated when
examining the same data in the following figure.

Figure 12: Averaged concentrations of Lcn2 detected in blood sera for treatment groups
over time.

Differences over time are more clearly perceived when the ELISA data for
different time points are graphed linearly. Again, the PBS control group experiences the
most dramatic decrease in measured protein during the course of this experiment. The
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pSecTagA vector only group, on average, also declines in Lcn2 expression in a similar
fashion even below measured basal levels, while the experimental group of pSecTagA
with Lcn2 increases at least 6 days following in vivo electroporation. The injection of 10
µg of pSecTagA-Lcn2 plasmid seems to be feasible for the initial overexpression of Lcn2
in the blood sera, though it is questionable whether the same or greater levels will be
stably expressed continuously.
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Discussion and Conclusions

It is significant to study potential biomarkers and their roles when examining the
key transition of colon cancer metastasis to the liver. If it is confirmed that the
upregulated presence of a target protein or other molecule coincides with the progression
to the exceedingly lethal stage of cancerous cells invading other organs, then its rapid
detection would be very useful in the clinical setting for early screening and treatment.
From previous studies involving the development of CT26-FL3 cells, a highly metastatic
cell line, the gene encoding the protein Lcn2 was found to be greatly expressed in the
metastatic liver both against other genes and the transcriptional genome of the sham
control group of mice that were not injected with CT26-FL3 cells.
In order to further study the role of Lcn2 in colon cancer metastasis to the liver,
both in vitro and in vivo experiments were performed. The first experiment involved
western blot analysis for intracellular protein detection of Lcn2 within CT26, CT26
mCherry, CT26 mCherry pCMV6 empty vector, CT26 mCherry pCMV6-Lcn2, CT26FL3, CT26-FL3 mCherry, CT26-FL3 mCherry pCMV6 empty vector, and CT26-FL3
mCherry pCMV6-Lcn2 transfected cell lines. Quantification of protein levels against
loading control β-actin for all samples by Image J indicated that Lcn2 expression remains
normalized between all cell types. However, RT-PCR for these CT26 derived cells
showed that the greatest levels of intracellular Lcn2 mRNA are being transcribed by the
higher metastatic CT26-FL3 cells with the pCMV6-Lcn2 plasmid vector overexpressing
Lcn2. When the same numbers of CT26 and CT26-FL3 cells are cultured and their media
collected at the same rates of confluency, the secretion of Lcn2 protein is also varied.
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Compared to the lower metastatic cell line, all CT26-FL3 derived cells secrete more
Lcn2, with the cells stably transfected with the Lcn2 promoting plasmid releasing the
highest concentration of Lcn2 into the media. These in vitro experiments indicate that
Lcn2 is positively associated with the greater tendency to metastasize by secreting the
protein (most likely) from the liver extracellularly in order to interact with other cells and
tissues.
To begin studying the effect of overexpressing Lcn2 on colon cancer metastasis
within the living mouse model, the plasmid pSecTagA-Lcn2 was constructed, purified,
and purified under large-scale endotoxin-free conditions to prepare for in vivo
electroporation. This method was chosen to be able to continuously express Lcn2 in the
bloodstream over extended periods of time via entry by a stable plasmid. Mice were
chosen to be in the following treatment groups: PBS only, 10 µg of pSecTagA empty
vector, and 10 µg of pSecTagA-Lcn2. These dosages were injected into the quadriceps
muscle of the mice and incorporated into the blood stream by in vivo electroporation at
100V for 50 ms. Blood was taken from the retro-orbital eye sinus 2 days before and 1, 4
and 6 days after surgery for further analysis of Lcn2 levels in the blood sera. Averaged
samples for each group measured from ELISA determined increasing circulation of Lcn2
in the blood stream for the experimental group injected with pSecTagA-Lcn2, while for
the other controls Lcn2 expression decreased at the 6 day mark. Due to these findings, in
vivo electroporation seems to be a viable method for the stable and continuous expression
of Lcn2.
Future experiments can continue directly from these conclusions. Increasing
dosages of treatments must be explored to find the maximal amount of plasmid that can
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be injected for the greatest, continuous expression of Lcn2 within the blood stream. The
results from these experiments can be analyzed with ELISA similar to my experiments
and compared for the most desired outcomes. Once this dosage has been discovered,
CT26 and CT26-FL3 tumor cells can be injected into the spleen when the Lcn2 serum
levels are most highly expressed. Following metastasis to the liver, the spleen and liver
can be harvested and weighed to examine rate of tumor growth with the diameters of the
primary tumors measured as well. It is predicted that the increased amounts of metastasis
will occur with the higher metastatic cell line at a greater frequency, though metastasis
may also be amplified compared to the usual 5% rate of metastasis for CT26 cells.
Conversely, analogous studies can be performed with Lcn2 inhibition whether it is by
Lcn2 gene knock out, silencing Lcn2 by siRNAs, or other similar methods to study the
influence of absence of Lcn2 in colon cancer metastasis to the liver. If these results
follow in line with current findings, rates of metastasis should decrease without stimulus
from Lcn2. Since Lcn2 limits bacterial growth by sequestering iron carrying
siderophores, it may alter cancerous cell proliferation by affecting iron in some way,
though this is entirely speculation at this point. Overall, these are merely the beginning
investigations on the role of Lcn2, though they show some promise in its possible crucial
involvement for the progression of colon cancer metastasis to the liver. Additional studies
must be undertaken to further elucidate Lcn2 exact molecular interactions within the
tumor microenvironment and beyond.
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